Breast Cancer News
Variations in the use and frequency of advanced imaging post-surgery in patients with breast cancer were observed across regions of the United States.
For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.
Updated results of the SOFT and TEXT trial suggest that adding ovarian suppression to exemestane or tamoxifen could improve survival outcomes.
The effectiveness of trastuzumab in retreating patients with recurrence who received it during perioperative therapy is the focus of a new study.
There are benefits and drawbacks to the public availability to DTC mutation tests.
Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26
The effect of combination chemotherapy and endocrine therapy has not been fully clarified among patients with Oncotype DX recurrence scores 11-25.
SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast Cancer
Despite modest improvements in progression-free survival, patients experienced considerable side effects with the addition of taselisib.
It is important to understand mechanisms of resistance with these inhibitors to determine future treatment strategies.
MONALEESA 3: Ribociclib Provides Significant PFS in Postmenopausal Women With ER+/HER- Advanced Breast Cancer Regardless of Prior Endocrine Therapy
With a greater than 40% decreased risk for disease progression, the combination of ribociclib and fulvestrant was significantly better than that of placebo and fulvestrant for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer.
Researchers assigned patients with various types of relapsed/refractory cancer to receive escalating doses of JTX-2011 alone or plus nivolumab.
Although progression-free survival was not significantly increased, long-term overall survival may be improved with pertuzumab.
Understanding various factors associated with unemployment may help to guide breast cancer management to increase the rate of returning to work.
Researchers determined that there was a significant association between overall survival and adjuvant RT when factoring in CTC status.
It was unknown whether breast cancer treatment plays a causal role in the onset of diabetes.
It was suggested that estrogen alone may have a protective effect, decreasing the risk of breast cancer by 8% with every year of use.
A previous analysis showed that APBI had non-inferior efficacy.
At the time of final analysis, 192 of 302 patients had died.
Improvements in alopecia were, however, seen in 37 of 46 patients treated with topical minoxidil.
Previous studies have demonstrated that sarcopenia, poor muscle quality, and excess adiposity are associated with higher mortality.
The median OS was not evaluable, though the estimated 2-year OS rate was 78.7%.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma
- First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy
- Triclosan and Cancer Risk: Is There a Link?
- Drugs Approved Under the Breakthrough Therapy Pathway Lack Basic Features of High-Quality Trials